Acanya
(clindamycin)ApprovedSmall molecule
PfizerThis medication combines an antibiotic and an antibacterial agent to treat acne by killing the bacteria responsible for the condition. It comes as a gel applied directly to the skin.[2] Acanya is currently approved and in use across 34 indications[4].[1]
Acanya is one of 616 small molecule programs targeting Cellulitis. It is currently in Approved.
34
Indications
69
Total Trials
12
Active Trials
615
Competitors
16
FDA Applications
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 34 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Halaven
EisaiPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Antibiotics4 trials
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2/3·NCT00729937·2,265 enrolled
Bacterial Vaginosis3 trials
Safety and Efficacy3 trials
Abscess2 trials
Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess
Terminated·—·N/A·NCT01498744·53 enrolled
48 more indications
Skin Infection2 trials
Methicillin-resistant Staphylococcus Aureus2 trials
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00730028·1,310 enrolled
Randomized Controlled Trial2 trials
Encephalitis2 trials
Prosthetic-joint Infection2 trials
Staphylococcus Aureus Bacteremia1 trial
Pneumonia1 trial
Malaria1 trial
Efficacy of Fosmidomycin-Clindamycin for Treating Malaria in Gabonese Children
Completed·—·Phase 3·NCT00214643·160 enrolled
Microbiota1 trial
Cellulitis1 trial
Adjunctive Clindamycin for Cellulitis: C4C Trial.
Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 4·NCT01876628·410 enrolled
Infants1 trial
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Recruiting·—··NCT03511118·1,600 enrolled
Pediatric1 trial
Urinary Tract Infection1 trial
Cardiac Surgery1 trial
Concentration1 trial
Clindamycin Vs Metronidazole1 trial
Dental Implant1 trial
Periodontitis1 trial
Neurosurgery1 trial
The Potential Impact of Clindamycin on Neurosurgery Patients.
Completed·—·N/A·NCT06068673·44 enrolled
Cesarean Section1 trial
Preoperative Clindamycin Vaginal Cream Versus Vaginal Cleansing With Povidone-iodine on Postoperative Infections After Cesarean Section
Recruiting·—·Phase 4·NCT07474194·150 enrolled
Efficacy and Safety1 trial
Critical Care1 trial
Drug Use Evaluation of Clindamycin in Critical Care Units in Alexandria Main University Hospital
Completed·—··NCT05223400·99 enrolled
Preoperative1 trial
Effect of Preoperative Clindamycin on Postoperative Endodontic Pain
Unknown status·—·Phase 2/3·NCT03033472·72 enrolled
Effectiveness1 trial
Peritonsillar Abscess1 trial
Antibiotic1 trial
Streptococcal Infections1 trial
Endocarditis1 trial
Carcinoma, Non-Small-Cell Lung1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
CLEOCIN PHOSPHATE
NDA NDA050441
Jan 1, 1982
CLEOCIN T
NDA NDA050537
Jan 1, 1982
CLEOCIN HYDROCHLORIDE
NDA NDA050162
Jan 7, 1987
CLEOCIN T
NDA NDA050615
May 31, 1989
CLEOCIN T
NDA NDA050600
Aug 30, 1989
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
NDA NDA050639
Dec 22, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
NDA NDA050636
Dec 22, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
NDA NDA050635
Dec 29, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
NDA NDA050648
Aug 11, 1992
CLEOCIN
NDA NDA050680
Aug 13, 1999
CLEOCIN
NDA NDA050767
Nov 27, 2000
CLINDAGEL
NDA NDA050782
Oct 22, 2004
EVOCLIN
NDA NDA050801
Nov 30, 2004
CLINDESSE
NDA NDA050793
Apr 20, 2017
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE
NDA NDA208083
Dec 7, 2021
XACIATO
NDA NDA215650
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Acanya drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for clindamycin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Acanya. U.S. Food & Drug Administration.
- [7]